Project Farma, PerkinElmer's life sciences consulting firm, has partnered with Oracle Primavera Cloud to enhance its project controls and capital programme delivery capabilities for pharmaceutical and biotech organisations. The collaboration expands Project Farma's Project Management Information System offering, combining integrated software and consulting solutions. Project Farma brings experience from over 100 facility builds and more than $6 billion in managed capital investments to the partnership. The company will provide a fully managed Oracle Primavera offering, delivering both platform technology and expertise for complex capital programmes. The service includes flexible options for PMIS implementation, project controls consulting and ongoing programme support. Clients receive a dedicated Oracle environment designed to protect project data whilst maintaining clean controls for inspection-ready facility delivery.

Interested in learning more about Project Farma? Contact Project Farma. Project Farma partners with Valkit.ai to modernize digital validation with AI. As AI continues to reshape digital validation across life sciences manufacturing, organizations are looking for modern, data-driven approaches to commissioning, qualification, and validation activities that can improve visibility, streamline execution, and reduce manual burden while maintaining compliance. To help support this industry shift, Project Farma has partnered with Valkit.ai, expanding its digital validation AI capabilities for pharmaceutical and biotech manufacturers. Valkit.ai develops digital validation technologies designed to support life sciences applications through modern, data-driven approaches to validation and compliance activities. By combining Project Farma's deep validation and manufacturing expertise with Valkit.ai's AI-driven platform, this partnership strengthens its ability to help clients streamline execution, improve traceability, reduce documentation burden, and accelerate the path to delivering therapies to patients. For clients, that means fewer delays and greater confidence in their validation programs. For patients, it means faster access to life-changing therapies. As digital validation AI tools become increasingly relevant across regulated manufacturing environments, Project Farma is committed to expanding its technology partnerships to ensure its clients have access to the most modern and effective approaches available. This partnership with Valkit.ai represents an important step in that direction, delivering a trusted and streamlined approach that supports faster project execution while maintaining the high standards required in regulated manufacturing environments. Click Here to read the full announcement on the PerkinElmer newsroom for additional details on the partnership and its significance for the future of digital validation in life sciences.

Delivering leaders to power Project Farma's onshoring expansion. March 12, 2026 Klein Hersh partnered with Project Farma, a leading engineering services provider supporting the biotech and pharmaceutical industries, to accelerate a large-scale leadership expansion during one of the most pivotal periods in U.S. biomanufacturing. Within months, its team successfully placed seven senior executives, with three outstanding searches underway, helping Project Farma scale its capabilities, deepen client engagement, and strengthen its position as a key driver of the nation's pharmaceutical reshoring movement. The Challenge: As U.S. policy and market forces drove pharmaceutical and biotechnology companies to reshore manufacturing operations, Project Farma faced a unique opportunity and challenge. The company, renowned for its engineering including project management and controls, CQV, quality and operational readiness expertise, was tasked with scaling quickly to meet surging demand from life sciences partners seeking to localize production and fortify supply chains. Having already partnered with Klein Hersh to recruit its Chief Operating Officer in April of 2025, Project Farma returned with an ambitious goal: hire ten senior leaders within two quarters. These included Vice Presidents of Technical Operations, Client Engagement, and Process & Manufacturing Sciences, as well as leaders in quality, CQV, operational excellence and other senior roles essential to driving strategic growth. The challenge was twofold: meeting the scale and speed of delivery required to sustain the company's momentum, while ensuring that each hire aligned with Project Farma's patient-focused, people-first, technically astute culture. Rapid expansion in a services organization demanded not only executional excellence but cultural stewardship, maintaining the collaborative and high-integrity ethos that defines the Project Farma brand. The Approach: Klein Hersh brought deep industry insight and a high-touch search process to deliver on Project Farma's accelerated hiring goals. * Strategic Context and Market Insight: Understanding the broader impact of the onshoring movement, Klein Hersh targeted leaders with the operational acumen and vision to support complex domestic manufacturing initiatives. Against a backdrop of historic investment across the life sciences sector, as organizations commit billions to reshore supply chains and expand U.S. production capacity, Project Farma needed executives who could guide clients through this transformation and large-scale growth. * Collaborative, Cross-Practice Execution: Leveraging its specialized networks, Klein Hersh, to date, has engaged over 850 candidates, streamlining outreach and selection to deliver results within an accelerated timeframe. Working closely with Project Farma's leadership, Klein Hersh International refined role requirements, aligned hiring priorities, and ensured quality and continuity across each placement. * Culture-Driven Fit: Beyond technical excellence, Klein Hersh International focused on candidates who could embody Project Farma's collaborative and entrepreneurial spirit. Every executive placed represented both the skill and mindset necessary to sustain the company's reputation for excellence and partnership in a rapidly evolving marketplace. The Results: Through this ongoing partnership, Klein Hersh has already placed seven senior leaders, with three outstanding searches in progress, a testament to both executional speed and long-term relationship strength. Early feedback from Project Farma leadership has underscored the exceptional caliber and cultural fit of each hire. Anshul Mangal, President at Project Farma, states, "Without much direction, Klein Hersh was able to quickly attack our search and identify leaders in life science manufacturing that were technically and culturally a great fit. The collaboration with Klein Hersh has directly impacted our ability to quickly respond to our pharma partner to scale facilities and infrastructure that will deliver life changing therapies." These placements are directly contributing to Project Farma's mission of enabling pharmaceutical and biotech organizations to bring advanced therapies to market faster, safer, and closer to home. The impact extends beyond one company. These hires are helping shape the next phase of U.S. life sciences manufacturing by ensuring that talent and leadership are aligned with the nation's onshoring priorities. While measurable growth data is forthcoming, the collaboration has already positioned Project Farma to capture significant new business opportunities, expand its service capabilities, and lead the next wave of innovation in biomanufacturing engineering and operational excellence. Looking Ahead As the reshoring of pharmaceutical and biotech manufacturing continues to reshape the industry, companies need more than recruiters. They need partners who understand both the science and the business of growth. Klein Hersh continues to serve as a trusted advisor to life sciences organizations, connecting transformative leadership talent with mission-critical opportunities in executive, fractional, and interim staffing. Contact Klein Hersh to discuss how Klein Hersh International can partner with your organization to build teams that power both innovation and long-term impact in life sciences and healthcare. Todd Rosengarten Todd Rosengarten is the leader of the non-small molecule CMC development, technical operations, and manufacturing practice at Klein Hersh. He joined Klein Hersh in 2008 and has driven the growth of the practice, working closely with large biopharma companies and small biotechs developing cell and gene therapy products and novel biologics drugs. As the leader of the non-small molecule CMC...